Ukwelapha i-HIV no-Odefsey

Ukuhlanganiswa Okuthuthukisiwe Izidakamizwa Zihlinzeka Ngezimbalwa Ezingezansi

Ukuhlukaniswa

I-Odefsey iyi-single-tablet, i-dose eqondile yokuhlanganiswa kwezidakamizwa ezisetshenziselwa ukwelashwa kwe-HIV, enama- antiretroviral amathathu ahlukene:

I-Odefsey iyisidakamizwa sesibili sokuhlanganisa ukusebenzisa i-TAF, inguqulo "ethuthukisiwe" ye-tenofovir disoproxil fumarate (TDF) etholakala kwizidakamizwa iTruvada ne- Atripla .

Njengalokhu, kungabhekwa njengokuthuthukiswa ku-Complera, ukwakheka kwethebhulethi eyodwa okuhlanganisa i-rilpivirine + emtricitabine + TDF.

I-TAF ibhekwa njengephakeme kune-TDF njengoba ikwazi ukuletha izidakamizwa ezisebenzayo ngokuphumelelayo emaqenjini nasezinkalweni ezincane kakhulu-okusho ukuthi kukhona ukuqoqwa okuncane kwesidakamizwa egazini kanye nethuba eliphansi lokuthuthukisa izidakamizwa eziphathelene nezinso ezihlobene nezidakamizwa.

(Nakuba ubungozi be-TDF obuhlobene ne-kidney toxicity bubhekwa njengamazwe asethuthukile, leyo ngozi ibonakala ikhula kakhulu emazweni asathuthuka lapho kunomthelela omkhulu wezifo ezingasebenzi ngaphambili.)

Isiqondiso Sokwelapha

U-Odefsey wamukelwa yi-US Food and Drug Administration ngoMashi 1, 2016 ukuze kusetshenziswe kokubili abadala nabantwana abangaphezu kweminyaka engu-12 abangakaze babe ne-HIV yokwelapha , abanomthwalo wegciwane wamangqamuzana angu-100 000 / m noma ngaphansi Amakhilogremu angu-77 (35kg) noma ngaphezulu.

I-Odefsey ingasetshenziselwa ukuthatha indawo yokwelashwa kwamanje (njengalezo eziseComplera) uma isiguli sinomthwalo wegciwane elingenakutholakali (<50 amaselula / mL) okungenani izinyanga eziyisithupha, awunalo umlando wokuhluleka kokwelashwa, futhi awunaziwa ukumelana nanoma yiziphi izidakamizwa ezitholakala e-Odefsey.

Ukubunjwa

I-Odefsey iyithebulethi eboshiwe, e-oblong, elinefilimu, enama-25mg we-rilpivirine, 200mg we-emtricitabine no-25 mg we-TAF.

Ihlanganiswa ne "GSI" ngakolunye uhlangothi futhi "255" ngakolunye uhlangothi.

Isilinganiso

Ithebulethi eyodwa nsuku zonke ithathwe ngokudla. U-Odefsey akufanele athathwe nanoma imuphi omunye umuthi we-antiretroviral osetshenziselwa ukuphatha i-HIV.

Okuqhamuka uma udla imishanguzo

Imithi emibi yemiphumela yezidakamizwa iye yaqashelwa ezigulini zesivivinyo somtholampilo ezithatha i-rilpivirine kanye / noma i-emtricitabine + i-TAF, ejwayelekile kunazo zonke:

Imiphumela emibi ngokuvamile yayihamba isikhathi eside, kanti iziguli ezimbalwa zayeka ngenxa yokungabekezelelani kwelashwa.

Ukungafani

U-Odefsey akufanele athathwe nalezi zidakamizwa noma izithako ezilandelayo:

Njalo utshele udokotela wakho nganoma yisiphi isidakamizwa noma ukwesekwa, okushiwo noma okungenqunyiwe, ukuthi ungathatha ngaphambi kokuqala noma yiluphi ukwelashwa kwama-antiretroviral.

Okunye okucatshangwayo

I-Odefsey ayinconywa iziguli ezinokukhubazeka kwezinso (ezichazwe njengokuthi imvume yokudalulwa kwama-creinine engaphansi kuka-30mL ngomzuzu).

Sicela ukutshela udokotela wakho uma ukhona noma ulashwa nganoma yisiphi isifo sezinso somunye udokotela.

I-Odefsey ayikhuthazwa iziguli ezinokukhubazeka kwesibindi noma kulabo abanesifo sengculaza esingapheli nesifo sohlobo lwe-hepatitis B (HBV) ngoba singabangela kakhulu izinkinga zesibindi. Kunconywa ukuthi abantu abane-HIV bahlolwe i-HBV ngaphambi kokubeka u-Odefsey. Sicela utshele udokotela wakho uma unenkinga yesibindi kanye / noma umlando we-hepatitis.

I-rilpivirine ingxenye ye-Odefsy ingabangela ukusabela kwe-hypersensitivity kwinani elincane leziguli, ngokuvamile ngesimo sokuqhaqhazela, ukuvuvukala kweso ("amehlo e-pink"), ukuvuvukala ebusweni, umkhuhlane, noma ezinye izimpendulo.

Ngokujwayelekile, ukusabela kwe-hypersensitivity sekukhona amasonto angu-1-6 ngemuva kokuqala kokuthola ukwelashwa. Memeze udokotela wakho ngokushesha nganoma yiziphi izimpawu ezinjalo zivela. Ezimweni ezinzima, ukwelashwa kuyodingeka kuphele.

Imithombo:

Ama-Reuters. "I-BRIEF - I-Sciences eGileyadi ithi i-US FDA ivumela u-Odefsey." Ikhishwe ngomhla ka-1 Mashi, 2015.

I-Sciences yaseGileyadi. " Odefsey - Amaphuzu avelele ekuchazeni ulwazi." Foster City, California; kufinyelelwe kuMashi 18, 2016.